Evolution of Bullous Pemphigoid Clinical Pattern over Time: A 17-Year Single-Centre Retrospective Survey of 312 Cases.

Bullous pemphigoid Clinical diagnostic criteria Clinical spectrum Time-related evolution

Journal

Dermatology (Basel, Switzerland)
ISSN: 1421-9832
Titre abrégé: Dermatology
Pays: Switzerland
ID NLM: 9203244

Informations de publication

Date de publication:
2023
Historique:
received: 30 03 2022
accepted: 01 10 2022
pubmed: 10 12 2022
medline: 7 3 2023
entrez: 9 12 2022
Statut: ppublish

Résumé

Bullous pemphigoid (BP) clinical profile may have evolved during the last 2 decades. A retrospective, single-centre analysis investigated a possible shift of clinical presentation of the disease over time regarding both lesions' clinical pattern and locations and more particularly an increased frequency of characteristics considered as less classical regarding the usual clinical description of BP. Initial clinical data from all BP patients treated between January 2001 and April 2017 in a reference centre were collected and compared between four 4-year successive chronological subsets (G1 to G4). 213/312 patients retained for final analysis (68.3%) displayed at least one initial non-classical characteristic, mainly head and neck, palmo-plantar, and/or mucosal involvement. Chronological analysis confirmed a significant increase over time of the percentage of patients displaying such features (G1 57.9% vs. G4 73.7%, p = 0.041). Changes in BP clinical pattern may have occurred over the last two decades with the progressive emergence of forms with a number of less classical features. No significant clinical difference was observed between patients receiving or not DPP4 inhibitors at the time of diagnosis.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
Bullous pemphigoid (BP) clinical profile may have evolved during the last 2 decades. A retrospective, single-centre analysis investigated a possible shift of clinical presentation of the disease over time regarding both lesions' clinical pattern and locations and more particularly an increased frequency of characteristics considered as less classical regarding the usual clinical description of BP.
PATIENTS AND METHODS METHODS
Initial clinical data from all BP patients treated between January 2001 and April 2017 in a reference centre were collected and compared between four 4-year successive chronological subsets (G1 to G4).
RESULTS RESULTS
213/312 patients retained for final analysis (68.3%) displayed at least one initial non-classical characteristic, mainly head and neck, palmo-plantar, and/or mucosal involvement. Chronological analysis confirmed a significant increase over time of the percentage of patients displaying such features (G1 57.9% vs. G4 73.7%, p = 0.041).
CONCLUSION CONCLUSIONS
Changes in BP clinical pattern may have occurred over the last two decades with the progressive emergence of forms with a number of less classical features. No significant clinical difference was observed between patients receiving or not DPP4 inhibitors at the time of diagnosis.

Identifiants

pubmed: 36481737
pii: 000527364
doi: 10.1159/000527364
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

235-240

Informations de copyright

© 2022 S. Karger AG, Basel.

Auteurs

Elise Dandache (E)

Department of Dermatology, University of Montpellier, Montpellier, France.

Aurélie Du Thanh (A)

Department of Dermatology, University of Montpellier, Montpellier, France.
INSERM U1058 Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, Montpellier, France.

Céline Girard (C)

Department of Dermatology, University of Montpellier, Montpellier, France.

Didier Bessis (D)

Department of Dermatology, University of Montpellier, Montpellier, France.

Olivier Dereure (O)

Department of Dermatology, University of Montpellier, Montpellier, France.
INSERM U1058 Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH